Barinthus Biotherapeutics

BRNSPhase 2

Founded 2021barinthusbio.com

Barinthus Biotherapeutics is a UK-based clinical-stage biotech formed in 2021 from the merger of Vaccitech plc and Avidea Technologies, combining complementary immunotherapeutic technologies. The company's mission is to advance antigen-specific immunotherapies that guide T cells to overcome autoimmunity and inflammatory diseases. It has reported positive interim and final data from Phase 1b/2 studies in hepatitis B and HPV, demonstrating favorable tolerability and immunogenicity. Barinthus is publicly traded (NASDAQ: BRNS) and is building a pipeline focused on immunology and inflammatory (I&I) indications.

Market Cap

$25.7M

Founded

2021

Focus

Cell & Gene TherapyVaccines

BRNS · Stock Price

USD 0.633.88 (-86.03%)

Historical price data

AI Company Overview

Technology Platform

Proprietary platforms including SNAP (Self-assembling Nanoparticle) for antigen delivery and immune modulation, and viral vectors (ChAdOx and MVA) for inducing and boosting T-cell responses, designed to guide the immune system to overcome chronic infection or autoimmunity.

Pipeline Snapshot

11 drugs in pipeline

Drug	Indication	Stage
MVA-NP+M1 + Saline	Influenza	Phase 2
ChAdOx1-HBV + MVA-HBV + Nivolumab	Chronic Hepatitis B	Phase 2
Seasonal influenza vaccine + MVA-NP+M1 + Sodium chloride	Influenza	Phase 2
MVA-NP+M1 + Saline + H3N2 (A/Belgium/2417/2015)	Influenza	Phase 2
ChAdOx1-MVA 5T4 vaccine + Nivolumab Infusion [Opdivo]	Intermediate Risk Prostate Cancer	Phase 1/2

Funding History

Total raised: $164M

IPO$75MUndisclosedOct 28, 2021

Series B$54MRA Capital ManagementFeb 15, 2021

Series A$35MGV (Google Ventures)Apr 15, 2019

Opportunities

Large unmet needs in chronic HBV (functional cure) and HPV-related diseases present significant market opportunities.

The SNAP platform offers potential expansion into a wide range of autoimmune and inflammatory conditions.

Validated viral vector technology (ChAdOx/MVA) could be leveraged for new infectious disease targets or through partnership deals.

Risk Factors

High clinical-stage risk with lead programs; failure in trials would be catastrophic.

Pre-revenue status necessitates future capital raises in potentially difficult markets.

Intense competition in core therapeutic areas from larger, better-resourced companies.

Competitive Landscape

Faces competition in HBV from Vir, Gilead, and Janssen, and in HPV vaccines from INOVIO. Differentiation lies in its combination of proven viral vector immunogenicity (ChAdOx/MVA) with a novel nanoparticle (SNAP) platform for precise immune guidance, targeting both infectious and autoimmune diseases.